CompletedInterventionalPhase 2Phase 3Last updated Apr 24, 2020

Baricitinib Therapy in COVID-19

Baricitinib Therapy in COVID-19: A Pilot Study on Safety and Clinical Impact

Overview

ClinicalTrials.gov ID: NCT04358614
Lead Sponsor: Fabrizio CantiniOTHER
Brief Summary: Retrospective study on the efficacy of baricitinib in 12 COVID-19 patients with moderate pneumonia.
Study Type: Interventional

Status

Study Record Dates

NCT04320277Unknown status

Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study.

NCT04393051Unknown status

Baricitinib Compared to Standard Therapy in Patients With COVID-19

NCT04340232Withdrawn

Safety and Efficacy of Baricitinib for COVID-19

NCT04373044Terminated

Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19

NCT04399798Unknown status

Baricitinib for coRona Virus pnEumonia (COVID-19): a THerapeutic Trial

NCT04421027Completed

A Study of Baricitinib (LY3009104) in Participants With COVID-19